Key facts
- Event
- CBA to face market on August 12
- Previous plunge
- 10.4% single-day drop, biggest ever
- Timing
- Almost three months since plunge
- Reasons for plunge
- Tepid quarterly update, surprise bad debts, federal tax concerns
- Focus stocks
- CBA and CSL
Background
Commonwealth Bank of Australia (CBA) is scheduled to face the market on August 12. That date will be almost three months to the day since the lender recorded its biggest-ever share price plunge, falling 10.4 per cent in a single day.
The May drop followed a tepid quarterly earnings update, a surprise rise in bad debts, and concerns about federal tax changes. The sharp decline was a shock to investors who had grown accustomed to CBA's stability.
CSL, the biotechnology company, is also a focus this profit season. Both stocks are considered bellwethers for the Australian market, and their results are closely watched by fund managers.
Current situation
According to a report from afr.com, fund managers are again betting big on the stock that broke their hearts – a reference to CBA. The report suggests that despite the earlier pain, investors are returning to the lender.
The article notes that it is an exaggeration to say the only results that really matter this profit season are CBA and CSL, but not by much. This underscores the outsized importance of these two companies to the market.
The exact size of the new bets or the number of fund managers involved has not been disclosed. The report does not specify which other stocks are also considered important this season.
Impacts
If CBA's upcoming results disappoint again, the bank's share price could suffer another sharp decline, affecting the broader Australian market given CBA's weight in the S&P/ASX 200 index.
A strong performance from CBA and CSL could restore investor confidence and support market sentiment, potentially benefiting other financial and healthcare stocks.
The federal tax changes that worried investors in May remain a factor. Any clarity on how these changes affect CBA's earnings could influence investment decisions across the banking sector.
Future outlook
Scenario analysis: The possibilities below are not certain predictions.
If CBA delivers a robust earnings update on August 12, the stock may recover further, and fund managers' renewed confidence could be justified. However, if bad debts rise again or tax concerns persist, the shares could face renewed selling pressure.
CSL's results could also shape market direction. If the biotech firm reports strong growth, it may lift healthcare stocks; if it disappoints, it could drag on the index.
The coming weeks will reveal whether the current bets are wise. Much depends on the actual numbers and the market's reaction, which remains uncertain.
Source: afr.com
